The ideal pharmacokinetic properties of an antiepileptic drug: How close does levetiracetam come?

Epileptic Disorders

Volumn 5, Issue SUPPL. 1, 2003, Pages

  Perucca, Emilio ^a   Johannessen, Svein I ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b National Center for Epilepsy   (Norway)

Author keywords

Antiepileptic drugs; Drug interactions; Levetiracetam; Pharmacokinetics; Review

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLASMA PROTEIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

BLOOD BRAIN BARRIER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG SENSITIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; KIDNEY; NONLINEAR SYSTEM; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; URINARY EXCRETION;

ACETIC ACIDS; AMINES; ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACIDS; DRUG INTERACTIONS; EPILEPSY; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HALF-LIFE; HUMANS; ISOXAZOLES; NIPECOTIC ACIDS; PIRACETAM; PROPYLENE GLYCOLS; TRIAZINES; VIGABATRIN;

EID: 0038722225     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Perucca E. Pharmacokinetics. In: Engel J Jr, Pedley TA. Epilepsy - A Comprehensive Textbook. New York: Raven Press, 1997: 1131-53.
2. Perucca E. Established antiepileptic drugs. In: Brodie MJ, Treiman DM. Modern Management of Epilepsy. Baillère's Clinical Neurology, vol 5. London: Baillière-Tindall, 1996: 693-722.
3. Buchtal F, Svensmark O, Schiller PJ. Clinical and electroencephalographic correlations of serum levels of diphenylhydantoin. Arch Neurol 1960; 2: 624-30.
4. Lund L. Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures. Arch Neurol 1974; 31: 289-94.
5. Feldman RG, Pippenger CE. The relation of anticonvulsant drug levels to complete seizure control. J Clin Pharmacol 1976; 16: 51-59.
6. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996; 42: 531-43.
7. Gatti G, Bonomi I, Jannuzzi G, et al. The new antiepileptic drugs: pharmacological and clinical aspects. Curr Pharm Des 2000; 6: 839-60.
8. Perucca E. The clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fund Clin Pharmacol 2001; 15: 405-17.
9. Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46: 409-27.
10. Adkins JC, Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998; 55: 437-60.
11. Perucca E. The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia 1999; 40(Suppl 9): S7-13.
12. Perucca E, Richens A. Biotransformation. In: Levy RH, Mattson RH, Meldrum B. Antiepileptic Drugs. New York: Raven Press, 1995: 31-50.
13. French JA, Gidal BE. Antiepileptic drug interactions. Epilepsia 2000; 41 (Suppl 8): S30-6.
14. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000; 85: 77-85.
15. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia 2001; 42(Suppl 4): 24-7.
16. Tong X, Patsalos PN. A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. Br J Pharmacol 2001; 133: 867-74.
17. Isoherranen N, Yagen B, Soback S, et al. Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs. Epilepsia 2001; 42: 825-30.
18. Dooley M, Plosker GL. Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. Drugs 2000; 60: 871-93.
19. Pellock JM, Glauser TA, Bebin EM, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia 2001; 42: 1574-9.
20. French J. Use of levetiracetam in special populations. Epilepsia 2001; 42 (Suppl 4): 40-3.
21. Nicolas JM, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 1999; 27: 250-4.
22. Perucca E, Gidal BE, Ledent E, et al. Levetiracetam does not interact with other antiepileptic drugs. Epilepsia 2000; 41 (Suppl 7): 254-5.
23. Browne TR, Szabo GK, Leppik IE, et al. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol 2000; 40: 590-5.
24. Giuliano RA, Hiersemenzel R, Baltes E, et al. Influence of a new antiepileptic drug (levetiracetam. Ucb L059) on the pharmacokinetics and pharmacodynamics of oral contraceptives. Epilepsia 1996; 37 (Suppl 4): 90.
25. Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res 2001; 46: 93-9.
26. Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res 2001; 47: 55-63.
27. Palmer KJ, McTavish D. Felbamate: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993; 45: 1041-65.
28. Perhach JL, Weliky I, Newton JJ, et al. Felbamate. In: Meldrum BS, Porter RJ. New Anticonvulsant Drugs. London: John Libbey, 1986: 117-25.
29. Sofia RD, Kramer L, Perhach JL, et al. Felbamate. Epilepsy Res 1991; 3(Suppl 3): 103-8.
30. Glue P, Banfield CR, Perhach JL, et al. Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation. Clin Pharmacokinet 1997; 33: 214-24.
31. Goa KL, Ross SR, Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46: 152-76.
32. Fitton A, Goa KL. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs 1995; 50: 691-713.
33. Bartoli A, Guerrini R, Belmonte A, et al. The influence of dosage, age and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit 1997; 19: 252-60.
34. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000; 41: 709-13.
35. Marcellin P, de Bony F, Garret C, et al. Influence of cirrhosis on lamotrigine pharmacokinetics. Br J Clin Pharmacol 2001; 51: 410-4.
36. Jawad S, Yuen WC, Peck AW, et al. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987; 1: 194-210.
37. Sabers A, Buchholt JM, Uldall P, et al. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001; 47: 151-4.
38. Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40: 1141-6.
39. Grants SM, Faulds D. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992; 43: 873-88.
40. Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 2001; 15: 137-63.
41. Rouan MC, Lecaillon JB, Godbillon J, et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 1994; 47: 161-7.
42. Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40: 783-7.
43. Gustavson LE, Boellner SW, Granneman GR, et al. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology 1997; 48: 1032-7.
44. Lau AH, Gustavson LE, Sperelakis R, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997; 38: 445-51.
45. Perucca E, Bialer M. The pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 1996; 31: 29-46.
46. Schmidt D, Gram L, Brodie M, et al. Tiagabine in the treatment of epilepsy - a clinical review with a guide for the prescribing physician. Epilepsy Res 2000; 41: 245-51.
47. Perucca E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Epilepsia 1996; 37 (Suppl 2): S8-13.
48. Langtry HD, Gillis JC, Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997; 54: 752-73.
49. Grant SM, Heel RC. Vigabatrin. A review of its pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889-926.
50. Rey E, Pons G, Olive G. Vigabatrin. Clinical pharmacokinetics. Clin Pharmacokinet 1992; 23: 267-78.
51. Gatti G, Bartoli A, Marchiselli R, et al. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol 1993; 36: 603-6.
52. Peters DH, Sorkin EM. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993; 45: 760-87.
53. Kasteleijn-Nolst Trenité DG, Marescaux C, Stodieck S, et al. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996; 25: 225-30.
54. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000; 38: 191-204.
55. Tomson T, Johannessen SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol 2000; 55: 697-705.